{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:25:54Z","timestamp":1793190354489,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Assessment of immune correlates of severe COVID-19 has been hampered by the low numbers of severe cases in COVID-19 vaccine efficacy (VE) trials. We assess neutralizing and binding antibody levels at 4 weeks post-Ad26.COV2.S vaccination as correlates of risk and of protection against severe-critical COVID-19 through 220 days post-vaccination in the ENSEMBLE trial (NCT04505722), constituting ~4.5 months longer follow-up than our previous correlates analysis and enabling inclusion of 42 severe-critical vaccine-breakthrough cases. Neutralizing antibody titer is a strong inverse correlate of severe-critical COVID-19, with estimated hazard ratio (HR) per 10-fold increase 0.35 (95% CI: 0.13, 0.90). In a multivariable model, HRs are 0.31 (0.11, 0.89) for neutralizing antibody titer and 1.22 (0.49, 3.02) for anti-Spike binding antibody concentration. VE against severe-critical COVID-19 rises with neutralizing antibody titer: 63.1% (95% CI: 40.0%, 77.3%) at unquantifiable [&lt;4.8975 International Units (IU)50\/ml], 85.2% (47.2%, 95.3%) at just-quantifiable (5.2 IU50\/ml), and 95.1% (81.1%, 96.9%) at 90\n                    <jats:sup>th<\/jats:sup>\n                    percentile (30.2 IU50\/ml). At the same titers, VE against moderate COVID-19 is 32.5% (11.8%, 48.4%), 33.9% (19.1%, 59.3%), and 60.7% (40.4%, 76.4%). Protection against moderate vs. severe disease may require higher antibody levels, and very low antibody levels and\/or other immune responses may associate with protection against severe disease.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-53727-y","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T07:03:10Z","timestamp":1731394990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-5925","authenticated-orcid":false,"given":"Lindsay N.","family":"Carpp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Hyrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-8343","authenticated-orcid":false,"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8523-1528","authenticated-orcid":false,"given":"Daniel J.","family":"Stieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Van Dromme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet A.","family":"Van Roey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-7502","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-0953","authenticated-orcid":false,"given":"Marco","family":"Carone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-9117","authenticated-orcid":false,"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Houchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obrimpong","family":"Amoa-Awua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mursal","family":"Naisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Narpala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Serebryannyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8045-1754","authenticated-orcid":false,"given":"Mike","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-8090","authenticated-orcid":false,"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Luedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-2915","authenticated-orcid":false,"given":"Michal","family":"Juraska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-2789","authenticated-orcid":false,"given":"Nima S.","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-5737","authenticated-orcid":false,"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-4386","authenticated-orcid":false,"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-5231","authenticated-orcid":false,"given":"Aditya H.","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdilea G.","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-3734","authenticated-orcid":false,"given":"April K.","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Andrasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Truyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vandebosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-0260","authenticated-orcid":false,"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":false,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4073-0393","authenticated-orcid":false,"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-8312","authenticated-orcid":false,"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-9427","authenticated-orcid":false,"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Immune Assays Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Coronavirus Vaccine Prevention Network (CoVPN)\/ENSEMBLE Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Van Dromme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet A.","family":"Van Roey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the United States Government (USG)\/CoVPN Biostatistics Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"53727_CR1","doi-asserted-by":"crossref","unstructured":"Plotkin, S. A. & Gilbert, P. B. \u201cCorrelates of Protection\u201d in Plotkin\u2019s Vaccines (Seventh Edition). S. A. Plotkin, W. A. Orenstein, P. A. Offit, K. M. Edwards, Eds. (Elsevier, 2018), 3.","DOI":"10.1016\/B978-0-323-35761-6.00003-1"},{"key":"53727_CR2","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"53727_CR3","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMp2211314","volume":"387","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. A Covid-19 milestone attained \u2014 A correlate of protection for vaccines. N. Engl. J. Med. 387, 2203\u20132206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"53727_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med"},{"key":"53727_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMoa2117608","volume":"386","author":"J Sadoff","year":"2022","unstructured":"Sadoff, J. et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N. Engl. J. Med. 386, 847\u2013860 (2022).","journal-title":"N. Engl. J. Med"},{"key":"53727_CR6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Y Fong","year":"2022","unstructured":"Fong, Y. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 7, 1996\u20132010 (2022).","journal-title":"Nat. Microbiol."},{"key":"53727_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade9078","volume":"15","author":"D Benkeser","year":"2023","unstructured":"Benkeser, D. et al. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci. Transl. Med. 15, eade9078 (2023).","journal-title":"Sci. Transl. Med."},{"key":"53727_CR8","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.vaccine.2024.02.071","volume":"42","author":"PB Gilbert","year":"2024","unstructured":"Gilbert, P. B. et al. Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial. Vaccine 42, 2181\u20132190 (2024).","journal-title":"Vaccine"},{"key":"53727_CR9","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/biom.13375","volume":"77","author":"NS Hejazi","year":"2021","unstructured":"Hejazi, N. S., van der Laan, M. J., Janes, H. E., Gilbert, P. B. & Benkeser, D. C. Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials. Biometrics 77, 1241\u20131253 (2021).","journal-title":"Biometrics"},{"key":"53727_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"53727_CR11","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange, E. M. et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med 27, 1280\u20131289 (2021).","journal-title":"Nat. Med"},{"key":"53727_CR12","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.3390\/ijms23137155","volume":"23","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. Early and polyantigenic CD4 T cell responses correlate with mild disease in acute COVID-19 donors. Int J. Mol. Sci. 23, 7155 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"53727_CR13","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012.e1019 (2020).","journal-title":"Cell"},{"key":"53727_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41590-021-01084-z","volume":"23","author":"Y Peng","year":"2022","unstructured":"Peng, Y. et al. An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat. Immunol. 23, 50\u201361 (2022).","journal-title":"Nat. Immunol."},{"key":"53727_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang, A. et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 23, 381\u2013396 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"53727_CR16","doi-asserted-by":"crossref","unstructured":"Pierre, C. N. et al. Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions. PLoS Pathog. 20, e1011569 (2024).","DOI":"10.1371\/journal.ppat.1011569"},{"key":"53727_CR17","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med 27, 1205\u20131211 (2021).","journal-title":"Nat. Med"},{"key":"53727_CR18","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"53727_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37176-7","volume":"14","author":"D Cromer","year":"2023","unstructured":"Cromer, D. et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nat. Commun. 14, 1633 (2023).","journal-title":"Nat. Commun."},{"key":"53727_CR20","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"E Hariton","year":"2018","unstructured":"Hariton, E. & Locascio, J. J. Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG 125, 1716 (2018).","journal-title":"BJOG"},{"key":"53727_CR21","doi-asserted-by":"publisher","first-page":"e1004107","DOI":"10.1371\/journal.pmed.1004107","volume":"19","author":"I Bergeri","year":"2022","unstructured":"Bergeri, I. et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med 19, e1004107 (2022).","journal-title":"PLoS Med"},{"key":"53727_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03154-6","volume":"11","author":"Y Huang","year":"2021","unstructured":"Huang, Y. et al. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci. Rep. 11, 23921 (2021).","journal-title":"Sci. Rep."},{"key":"53727_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59\u201374 (1977).","journal-title":"J. Gen. Virol."},{"key":"53727_CR24","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1073\/pnas.0630530100","volume":"100","author":"DD Richman","year":"2003","unstructured":"Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144\u20134149 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"53727_CR25","unstructured":"National Institute for Biological Standards and Control (NIBSC). Instructions for use of First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17\/12\/2020) NIBSC code: 20\/136 https:\/\/www.nibsc.org\/science_and_research\/idd\/cfar\/covid-19_reagents.aspx Access date Jul 29, 2021."},{"key":"53727_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"53727_CR27","unstructured":"R. Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/ (2020)."},{"key":"53727_CR28","doi-asserted-by":"crossref","unstructured":"Lumley, T. Complex Surveys: A Guide to Analysis Using R (565, John Wiley & Sons, 2010).","DOI":"10.1002\/9780470580066"},{"key":"53727_CR29","doi-asserted-by":"crossref","unstructured":"Kenny, A. vaccine: Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data. R package version 1.2.1. https:\/\/CRAN.R-project.org\/package=vaccine (2024).","DOI":"10.32614\/CRAN.package.vaccine"},{"key":"53727_CR30","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/biostatistics\/kxac024","volume":"24","author":"PB Gilbert","year":"2023","unstructured":"Gilbert, P. B., Fong, Y., Kenny, A. & Carone, M. A controlled effects approach to assessing immune correlates of protection. Biostatistics 24, 850\u2013865 (2023).","journal-title":"Biostatistics"},{"key":"53727_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/biom.13690","volume":"79","author":"L van der Laan","year":"2023","unstructured":"van der Laan, L., Zhang, W. & Gilbert, P. B. Nonparametric estimation of the causal effect of a stochastic threshold-based intervention. Biometrics 79, 1014\u20131028 (2023).","journal-title":"Biometrics"},{"key":"53727_CR32","doi-asserted-by":"crossref","unstructured":"Kenny, A. PhD dissertation, Department of Biostatistics, University of Washington. Statistical tools for immune correlates analysis of vaccine clinical trial data (2023).","DOI":"10.32614\/CRAN.package.vaccine"},{"key":"53727_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: Introducing the E-value. Ann. Intern Med. 167, 268\u2013274, (2017).","journal-title":"Ann. Intern Med."},{"key":"53727_CR34","doi-asserted-by":"publisher","unstructured":"USG COVID-19 Response Team \/ Coronavirus Prevention Network (CoVPN) Biostatistics Team. USG COVID-19 Response Team \/ CoVPN Vaccine Efficacy Trial Immune Correlates Statistical Analysis Plan. figshare. Online resource. https:\/\/doi.org\/10.6084\/m9.figshare.13198595.v13 Last updated 18 Apr, 2022. Access date 10 Jun, 2022.","DOI":"10.6084\/m9.figshare.13198595.v13"},{"key":"53727_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1541-0420.2011.01685.x","volume":"68","author":"ID Munoz","year":"2012","unstructured":"Munoz, I. D. & van der Laan, M. Population intervention causal effects based on stochastic interventions. Biometrics 68, 541\u2013549 (2012).","journal-title":"Biometrics"},{"key":"53727_CR36","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1002\/sim.5907","volume":"32","author":"S Haneuse","year":"2013","unstructured":"Haneuse, S. & Rotnitzky, A. Estimation of the effect of interventions that modify the received treatment. Stat. Med 32, 5260\u20135277 (2013).","journal-title":"Stat. Med"},{"key":"53727_CR37","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.21105\/joss.02447","volume":"5","author":"NS Hejazi","year":"2020","unstructured":"Hejazi, N. S. & Benkeser, D. txshift: Efficient estimation of the causal effects of stochastic interventions in R. J. Open Source Softw. 5, 2447 (2020).","journal-title":"J. Open Source Softw."},{"key":"53727_CR38","doi-asserted-by":"publisher","unstructured":"Hejazi, N. & Benkeser, D. txshift: Efficient Estimation of the Causal Effects of Stochastic Interventions (version 0.3.8). https:\/\/doi.org\/10.5281\/zenodo.4070042 (2023).","DOI":"10.5281\/zenodo.4070042"},{"key":"53727_CR39","doi-asserted-by":"publisher","unstructured":"Coyle, J. R., Hejazi, N., Malenica, I., Phillips, R. V. & Sofrygin, O. sl3: Super Machine Learning with Pipelines (version 1.4.6). https:\/\/doi.org\/10.5281\/zenodo.1342293 (2023).","DOI":"10.5281\/zenodo.1342293"},{"key":"53727_CR40","doi-asserted-by":"crossref","unstructured":"Ihaka, R. & Gentleman, R. R: a language for data analysis and graphics. 5 (Taylor & Francis, 1996).","DOI":"10.2307\/1390807"},{"key":"53727_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijid.2023.09.012","volume":"137","author":"NS Hejazi","year":"2023","unstructured":"Hejazi, N. S. et al. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. Int J. Infect. Dis. 137, 28\u201339 (2023).","journal-title":"Int J. Infect. Dis."},{"key":"53727_CR42","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3390\/v15102029","volume":"15","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 trial. Viruses 15, 2029 (2023).","journal-title":"Viruses"},{"key":"53727_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/biomet\/69.2.331","volume":"69","author":"RL Prentice","year":"1982","unstructured":"Prentice, R. L. Covariate measurement errors and parameter estimation in a failure time regression model. Biometrika 69, 331\u2013342 (1982).","journal-title":"Biometrika"},{"key":"53727_CR44","doi-asserted-by":"publisher","unstructured":"Huang, Y. & Follmann, D. Exposure proximal immune correlates analysis. kxae031. Biostatistics, https:\/\/doi.org\/10.1093\/biostatistics\/kxae031 (2024).","DOI":"10.1093\/biostatistics\/kxae031"},{"key":"53727_CR45","doi-asserted-by":"publisher","unstructured":"Fong, Y. et al. CoVPN\/correlates_reporting2: Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.13690802 (2024).","DOI":"10.5281\/zenodo.13690802"},{"key":"53727_CR46","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.21105\/joss.02447","volume":"5","author":"NS Hejazi","year":"2020","unstructured":"Hejazi, N. S. & Benkeser, D. txshift: Efficient estimation of the causal effects of stochastic interventions inR. J. Open Source Softw. 5, 2447 (2020).","journal-title":"J. Open Source Softw."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53727-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53727-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53727-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T19:03:30Z","timestamp":1731783810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53727-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53727"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53727-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"16 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.H. is an employee of Janssen Vaccines & Prevention BV and has stock and\/or stock options in Johnson & Johnson. S.R., I.V.D., and C.T. are employees of Janssen Pharmaceuticals and have stock and\/or stock options in Johnson & Johnson. F.S. was an employee of J&J at the time the study was conducted and has stock and\/or stock options in Johnson & Johnson. F.S. also has shares in GlaxoSmithKline as compensation for past employment. D.J.S., G.A.V.R., J.S., H.S., and M.D. were employees of Janssen Vaccines & Prevention BV and had stock and\/or stock options in Johnson & Johnson at the time the work was conducted. J.S. has patents (US 11,384,122 B2) on invention of the Janssen COVID-19 vaccine. A.V. was an employee of Janssen Pharmaceuticals, had stock and\/or stock options in Johnson & Johnson at the time the work was conducted, and had all patent rights (US 11,384,122 B2) transferred to Johnson & Johnson. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The COV3001 (ENSEMBLE) study was reviewed and approved by all relevant local ethics committees and Institutional Review Boards, listed below: Argentina: ANMAT - Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnologia M\u00e9dica (Capital Federal, La Plata, Ramos Mejia\u2014Buenos Aires; Ciudad Autonoma de Buenos Aires), Comite de Etica Dr Carlos Barclay (Capital Federal, Buenos Aires; Ciudad Autonoma de Buenos Aires), Comision Conjunta de Investigacion en Salud\u2014CCIS (La Plata, Ramos Mejia\u2013Buenos Aires), Comite de Bioetica de Fundacion Huesped (Ciudad Autonoma de Buenos Aires), Comit\u00e9 de Docencia e Investigaci\u00f3n DIM Cl\u00ednica Privada (Ramos Mejia, Buenos Aires), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n Cl\u00ednica y Maternidad Suizo Argentina (Ciudad Autonoma de Buenos Aires), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n de CEMIC (Ciudad Autonoma de Buenos Aires), Comite de Etica en Investigacion DIM Clinica Privada (Ramos Mejia, Buenos Aires), Comite de Etica Hospital Italiano de La Plata (La Plata, Buenos Aires), Comite de Etiica en Investigacion Hospital General de Agudos J.M. Ramos Mejia (Ciudad Autonoma de Buenos Aires), Comit\u00e9de \u00e9tica del Instituto M\u00e9dico Platense (CEDIMP) (La Plata, Buenos Aires), IBC Fundacion Huesped (Ciudad Autonoma de Buenos Aires), IBC Helios Salud (Ciudad Autonoma de Buenos Aires), IBC Hospital General de Agudos J.M. Ramos Mejia (Ciudad Autonoma de Buenos Aires) Brazil: ANVISA \u2013 Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Salvador, Bahia; Barretos, Campinas, S\u00e3o Paulo, S\u00e3o Jose Rio Preto, Ribeir\u00e3o Preto, S\u00e3o Caetano do Sul \u2013 S\u00e3o Paulo; Santa Maria, Porto Alegre \u2013 Rio Grande do Sul; Natal, Rio Grande do Norte; Para, Par\u00e1; Belo Horizonte, Minas Gerais; Rio de Janeiro, Nova Igua\u00e7u \u2013 Rio de Janeiro; Curitiba, Paran\u00e1; Bras\u00edlia, Distrito Federal; Campo Grande, Mato Grosso do Sul; Crici\u00fama, Santa Catarina; Cuiab\u00e1, Mato Grosso), CONEP - Comiss\u00e3o Nacional de \u00c9tica em Pesquisa (Salvador, Bahia; S\u00e3o Paulo, S\u00e3o Paulo; Santa Maria, Rio Grande do Sul; Para, Par\u00e1;), CAPPESq \u2013 Comiss\u00e3o de \u00c9tica de An\u00e1lise para Projetos de Pesquisa\u2014HCFMUSP (S\u00e3o Paulo, S\u00e3o Paulo), CEP da Faculdade de Medicina de S\u00e3o Jos\u00e9 do Rio Preto \u2013 FAMERP (S\u00e3o Jose Rio Preto, S\u00e3o Paulo), CEP da Faculdade de Medicina do ABC\/SP (S\u00e3o Paulo, S\u00e3o Paulo), CEP da Funda\u00e7\u00e3o Pio XII - Hospital do C\u00e2ncer de Barretos\/SP (Barretos, S\u00e3o Paulo), CEP da Liga Norteriograndense Contra o C\u00e2ncer (Natal, Rio Grande do Norte), CEP da Pontificia Universidade Catolica de Campinas \/ PUC Campinas (Campinas, S\u00e3o Paulo), CEP da Real Benem\u00e9rita Associa\u00e7ao Portuguesa de Benefic\u00eancia - Hospital S\u00e3o Joaquim (S\u00e3o Paulo, S\u00e3o Paulo), CEP da Santa Casa de Miseric\u00f3rdia de Belo Horizonte (Belo Horizonte, Minas Gerais), CEP da Secretaria Municipal De Sa\u00fade do Rio de Janeiro\u2014SMS\/RJ (Rio de Janeiro, Rio de Janeiro), CEP da Universidade de S\u00e3o Caetano do Sul (CEP da Universidade de S\u00e3o Caetano do Sul, S\u00e3o Paulo), CEP da Universidade Federal de Mato Grosso do Sul\u2014UFMS (Campo Grande, Mato Grosso do Sul), CEP da Universidade Federal de Minas Gerais (Belo Horizonte, Minas Gerais), CEP do Centro de Refer\u00eancia e Treinamento DST\/AIDS (S\u00e3o Paulo, S\u00e3o Paulo), CEP do do INI-Ipec\/Fiocruz (Rio de Janeiro, Rio de Janeiro), CEP do Grupo Hospitalar Concei\u00e7\u00e3o \/ RS (Porto Alegre, Rio Grande do Sul), CEP do Hospital das Cl\u00ednicas da Faculdade de Medicina de Ribeir\u00e3o Preto\/USP (Ribeir\u00e3o Preto, S\u00e3o Paulo), CEP do Hospital de Clinicas da Universidade Federal do Parana\u2014HCUFPR \/ PR (Curitiba, Paran\u00e1), CEP do Hospital de Cl\u00ednicas de Porto Alegre\/HCPA (Porto Alegre, Rio Grande do Sul), CEP do Hospital Geral de Nova Igua\u00e7u (Nova Igua\u00e7u, Rio do Janeiro), CEP do Hospital Municipal S\u00e3o Jos\u00e9 (Crici\u00fama, Santa Catarina), CEP do Hospital Pr\u00f3-Card\u00edaco\/RJ (Rio de Janeiro, Rio de Janeiro), CEP do Hospital S\u00edrio Liban\u00eas (S\u00e3o Paulo, Sao Paulo), CEP do Hospital Universit\u00e1rio J\u00falio Muller \/ MT (Cuiab\u00e1, Mato Grosso), CEP do Hospital Universit\u00e1rio Professor Edgard Santos\u2014UFBA (Salvador, Bahia), CEP do Instituto de Cardiologia do Distrito Federal (Bras\u00edlia, Distrito Federal), CEP do Instituto de Infectologia Em\u00edlio Ribas\/SP (S\u00e3o Paulo, Sao Paulo), CEP do Instituto de Saude e Bem Estar da Mulher - ISBEM \/ SP (S\u00e3o Paulo, Sao Paulo), CEP em Seres Humanos do HFSE - Hospital Federal dos Servidores do Estado (Rio de Janeiro, Rio de Janeiro), CONEP - Comiss\u00e3o Nacional de \u00c9tica em Pesquisa (Bras\u00edlia, Distrito Federal, Salvador, Bahia; Belo Horizonte, Minas Gerais; Cuiab\u00e1, Mato Grosso; Campo Grande, Mato Grosso do Sul; Nova Igua\u00e7u, Rio Janeiro\u2014Rio Janeiro; Barretos, Campinas, Sao Jose Rio Preto, S\u00e3o Caetano do Sul, Sao Paulo, Ribeir\u00e3o Preto\u2014Sao Paulo; Porto Alegre, Rio Grande do Sul; Natal, Rio Grande do Norte; Curitiba, Paran\u00e1; Crici\u00fama, Santa Catarina) Chile: Comit\u00e9 de \u00c9tica de Investigaci\u00f3n en Seres Humanos (Santiago, Region Met), Comit\u00e9 \u00c9tico Cient\u00edfico Servicio de Salud Metropolitano Central (Santiago, Region Met), Instituto de Salud P\u00fablica de Chile (Santiago, Region Met; Talca, Temuco), Comit\u00e9 \u00c9tico-Cient\u00edfico Servicio de Salud Metropolitano Sur Oriente (Talca, Santiago), Comit\u00e9 de Evaluaci\u00f3n \u00c9tica Cient\u00edfica Servicio de Salud Araucan\u00eda Sur Temuco (Temuco), Comit\u00e9 \u00c9tico Cient\u00edfico Servicio de Salud Metropolitano Central (Vi\u00f1a del Mar) Colombia: CEI de la Fundaci\u00f3n Cardiovascular de Colombia (Floridablanca), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n Cl\u00ednica de la Costa (Barranquilla), INVIMA\u2014Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Barranquilla), Comite de Etica en Investigacion de la E.S.E. Hospital Mental de Antioquia (Santa Marta), Comite de Etica en la Investigacion CAIMED (Bogot\u00e1), INVIMA\u2014Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Bogot\u00e1), Comite Corporativo de Etica en Investigacion de la Fundacion Santa Fe de Bogota (Bogot\u00e1), Comit\u00e9 de \u00c9tica e Investigaci\u00f3n Biom\u00e9dica de la Fundaci\u00f3n Valle del Lili (Cali), Comite de Etica e Investigacion IPS Universitaria (Medellin), Comite de Etica en Investigacion Asustencial Cientifica de Alta Complejidad (Bogot\u00e1), Comite de Etica en Investigacion Biomedica de la Corporacion Cientifica Pediatrica de Cali (Cali), Comit\u00e9 de \u00c9tica en Investigaci\u00f3n Cl\u00ednica de la Costa (Barranquilla), Comite de Etica en Investigacion de la E.S.E. Hospital Mental de Antioquia (Barrio Barzal Villavicencio), Comite de Etica en Investigacion del area de la Salud de la Universidad del Norte (Barranquilla), Comite de Etica en Investigacion Medplus Centro de Recuperaci\u00f3n Integral S.A.S (Bogot\u00e1), Comit\u00e9 de \u00c9tica en Investigaciones CEI-FOSCAL (Floridablanca), Comite de Etica en la Investigacion CAIMED (Bogot\u00e1), Comite de Etica para Investigacion Clinica(CEIC) de la Fundacion Centro de Investigacion Clinica CIC (Medellin), Comite de Investigaciones y Etica en Investigaciones Hospital Pablo Tobon Uribe (Medellin), INVIMA\u2013Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia) (Barranquilla, Bogot\u00e1), Cali, Floridablanca, Medellin Mexico: CEI del Hospital Civil de Guadalajara Fray Antonio Alcalde (Guadalajara, Jalisco), CEI Hospital La Mision (Tijuana, Baja California Norte), CI del Hospital Civil de Guadalajara Fray Antonio Alcalde (Guadalajara, Jalisco), CI Hospital La Mision (Tijuana, Baja California Norte), Comite de Bioseguridad del Instituto Nacional de Salud Publica (Mexico, Distrito Federal; Cuernavaca, Morelos), Comite de Etica en Investigacion del Instituto Nacional de Salud Publica (Mexico, Distrito Federal; Cuernavaca, Morelos), Comit\u00e9 de Bioseguridad del Hospital La Misi\u00f3n S.A. de C.V. (Tijuana, Baja California Norte; Oaxaca, Oaxaca; Merida, Yucat\u00e1n; Tijuana, Baja California Norte), Comit\u00e9 de Bioseguridad de la Coordinaci\u00f3n de Investigaci\u00f3n en Salud (IMSS) (Mexico, Estado de Mexico), Comit\u00e9 de Bioseguridad de M\u00e9dica Rio Mayo (CLINBOR) (Mexico, Distrito Federal), Comit\u00e9 de Bioseguridad del Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d (Monterrey, Nuevo Le\u00f3n), COFEPRIS (Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios) (Cuernavaca, Morelos; Mexico, Distrito Federal; Monterrey, Nuevo Le\u00f3n; Oaxaca, Oaxaca; Merida, Yucat\u00e1n), Comite de Etica de la Fac de Med de la UANL y Hospital Universitario \u201cDr. Jose Eleuterio Gonzalez\u201d (Monterrey, Nuevo Le\u00f3n), Comite de Etica en Investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C. (Merida, Yucat\u00e1n), Comite de Etica en Investigacion de Medica Rio Mayo S.C. (Mexico, Distrito Federal), Comite de Etica en Investigacion de Oaxaca Site Management Organization, S.C. (Oaxaca, Oaxaca), Comite de Etica en Investigacion del Centro Medico Nacional Siglo XXI (IMSS) (Mexico, Estado do Mexico), Comit\u00e9 de Investigaci\u00f3n de la Coordinaci\u00f3n de Investigaci\u00f3n en Salud (IMSS) (Mexico, Estado do Mexico), Comite de Investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C. (Merida, Yucat\u00e1n), Comite de Investigacion de Oaxaca Site Management Organization, S.C. (Oaxaca, Oaxaca), Comit\u00e9 de Investigaci\u00f3n del Hospital Universitario Jos\u00e9 Eleuterio Gonz\u00e1lez (Monterrey, Nuevo Le\u00f3n), Comite de Investigacion Medica Rio Mayo, S.C. (Mexico, Distrito Federal) Peru: Comite Nacional Transitorio de Etica en Invest. de los Ensayos Clinicos de la enfermedad COVID-19 (Iquitos\u2013Maynas, Loreto; Lima, San Miguel \u2013 Lima), INS - Instituto Nacional de Salud (Peru) (Lima, San Miguel \u2013 Lima; Callao; Iquitos\u2013Maynas, Loreto) South Africa: Department Agriculture, Forestry and Fisheries (DAFF) (Port Elizabeth, Mthatha \u2013 Eastern Cape; Cape Town, Worcester \u2013 Western Cape; Durban, Ladysmith, Vulindlela \u2013 KwaZulu-Natal; Johannesburg, Pretoria, Mamelodi East, Soweto, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), Pharma Ethics (Port Elizabeth, Eastern Cape; Durban, Ladysmith \u2013 KwaZulu-Natal; Cape Town, Western Cape; Pretoria, Mamelodi East, Johannesburg, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), SAHPRA - South African Health Products Regulatory Authority (Port Elizabeth, Mthatha \u2013 Eastern Cape; Cape Town, Worcester \u2013 Western Cape; Durban, Ladysmith, Vulindlela \u2013 KwaZulu-Natal; Johannesburg, Pretoria, Mamelodi East, Soweto, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Bloemfontein, Free State; Middelburg, Mpumalanga; Dennilton, Limpopo), WIRB (Mamelodi East, Pretoria \u2013 Gauteng; Ladysmith, KwaZulu-Natal; Bloemfontein, Free State; Cape Town, Western Cape; Dennilton, Limpopo), Wits Health Consortium (Soweto, Johannesburg \u2013 Gauteng; Ladysmith, KwaZulu-Natal; Mthatha, Eastern Cape), Wits Institutional Biosafety Committee (Soweto, Pretoria, Johannesburg, Tembisa \u2013 Gauteng; Rustenburg, Klerksdorp \u2013 North West; Mthatha, Eastern Cape), University of Cape Town HREC (Cape Town, Worcester \u2013 Western Cape); University of Cape Town Institute of Infectious Disease & Molecular Medicine (Cape Town, Worcester \u2013 Western Cape), University of Cape Town Institutional Biosafety Committee (Cape Town, Worcester \u2013 Western Cape), SAMRC Human Research Ethics Committee Scientific Review (Durban, KwaZulu-Natal), Sefako Makgatho University Research Ethics Committee (SMUREC) (Pretoria, Gauteng), University of KwaZulu Natal Institutional Biosafety Committee (Durban, KwaZulu-Natal), University of KwaZulu-Natal Ethics (Durban, Vulindlela \u2013 KwaZulu-Natal), University of Stellenbosch Ethics Committee (Cape Town, Western Cape), University of KwaZulu Natal Institutional Biosafety Committee (Vulindlela, KwaZulu-Natal) United States: Advarra IBC (Detroit, MI; Chapel Hill, NC; Boston, MA; Seattle, WA; Winston-Salem, NC; Austin, TX; Peoria, IL; Huntsville, AL; Long Beach, CA; Tucson, AZ), Biomedical Institute of New Mexico - IBC (Albuquerque, NM), Birmingham VA Medical Center - Alabama- IBC (Birmingham, AL), Clinical Biosafety Services (Hollywood, FL), Columbia University IBC (New York, NY), Copernicus Group IRB (Austin, Dallas, Houston, San Antonio \u2013 TX; Rochester, New York, Bronx, Binghamton \u2013 NY; Hillsborough, Hackensack, Newark, New Brunswick \u2013 NJ; West Palm Beach, Coral Gables, Hollywood, Miami, Orlando, Gainesville, Tampa, Hallandale Beach, Pinellas Park, The Villages, Jacksonville, Deland \u2013 FL; Fort Worth, Dallas, San Antonio \u2013 TX; Norfolk, Charlottesville \u2013 VA; Matairie, New Orleans \u2013 LA; Nashville, Knoxville, Memphis, Bristol \u2013 TN; Cincinnati, Cleveland, Columbus, Akron \u2013 OH; Detroit, Ann Arbor, Grand Rapids \u2013 MI; Philadelphia, Pittsburgh \u2013 PA; Stanford, San Diego, San Francisco, Oakland, Long Beach, Anaheim, Sacramento, West Hollywood \u2013 CA, Las Vegas, Reno \u2013 NV; Chicago, Peoria \u2013 IL; Omaha, NE; Mobile, Birmingham, Huntsville \u2013 AL; St Louis, Greer, Kansas City \u2013 MO; Boston, MA; Harrisburg, SD; Decatur, Atlanta, Savannah \u2013 GA; Baltimore, Rockville, Annapolis \u2013 MD; New Haven, Hartford \u2013 CT; Chapel Hill, Raleigh, Fayetteville, Charlotte, Durham, Winston-Salem \u2013 NC; Indianapolis, Valparaiso, Evansville \u2013 IN; Seattle, WA; Aurora, CO; Lexington, Louisville \u2013 KY; Murray, West Jordan, Salt Lake City \u2013 UT; Phoenix, Tucson, Glendale \u2013 AZ; Spartanburg, Columbia, North Charleston, Anderson, Charleston, Mount Pleasant \u2013 SC; Portland, Medford, Corvallis \u2013 OR; Albuquerque, Gallup \u2013 NM; Little Rock, AR; Jackson, MS; Newport News, VA, Minneapolis, MN; Lenexa, KS), WIRB (Hackensack, NJ; Dallas, TX; Baltimore, MD; Chicago, IL; Aurora, CO; Winston-Salem, NC; Minneapolis, MN; Orlando, Miami, Gainesville \u2013 FL; Philadelphia, Pittsburgh \u2013 PA; Boston, MA; St Louis, MO; Bronx, New York, NY; New Brunswick, NJ; Phoenix, AZ; Birmingham, AL; Louisville, KY; Albuquerque, NM; New Orleans, LA; Baltimore, MD; San Francisco, CA; Tampa, FL; Aurora, CO; Columbia, SC; Decatur, GA; Reno, NV; Raleigh, NC; Little Rock, AS), Clinical Biosafety Services (Dallas, San Antonio \u2013 TX; San Diego, CA; Lexington, KY; Murray, UT; Greer, Kansas City, St Louis \u2013 MO; Rockville, MD; Las Vegas, NV; Cincinnati, Columbus, Akron \u2013 OH; Phoenix, Tucson, Glendale \u2013 AZ; North Charleston, Anderson \u2013 SC; Orlando, Pinellas Park, The Villages, Miami \u2013 FL; Birmingham, AL; Valparaiso, Evansville \u2013 IN; Lenexa, KS), Columbia University IBC (Bronx, New York), Durham VA Medical Center-IBC (Raleigh, NC), Emory University IRB (Decatur, GA), Environmental Health and Safety Office (Atlanta, GA), Institutional Biosafety Committee (New Orleans, LA), James A. Haley Veterans Hospital_IBC (Tampa, FL), Jesse Brown VA Medical Center- IBC (Chicago, IL), Mass General Brigham IBC (Boston, MA), Mount Sinai- Icahn School of Medicine IBC (New York, NY), New York Blood Center IBC (New York, NY), OHSU IBC (Portland, OR), Partners Institutional Biosafety Committee (Boston, MA), Rocky Mountain Regional VA Medical Center-IBC (Aurora, CO), Rush University Medical Center (Chicago, IL), Rush University Medical Center IBC (Chicago, IL), Rutgers Institutional Biosafety Committee (New Brunswick, NJ), Saint Louis University IBC (St Louis, MO), Saint Michael\u2019s Medical Center IRB (Newark, NJ), Southeast Louisiana Veterans Health Care System IBC (New Orleans, LA), St. Jude Children\u2019s Research Hospital IBC Committee (Memphis, TN), St. Jude Children\u2019s Research Hospital IRB (Memphis, TN), Stanford University Administrative Panel on Human Subjects in Medical Research (Stanford, CA), Temple University\u2013IBC (Philadelphia, PA), The University of Chicago Institutional Biosafety Committee (Chicago, IL), UAMS IBC (Little Rock, AS), UIC IBC (Chicago, IL), University of Alabama at Birmingham Institutional Biosafety Committee (Birmingham, AL), University of Arkansas IRB (Little Rock, AS), University of Kentucky Biological Safety (Lexington, KY), University of Kentucky IRB (Lexington, KY), University of Louisville IRB (Louisville, KY), University of Miami-IBC (Miami, FL), University of Mississippi Medical Center IRB (Jackson, MI), University of Pennsylvania Institutional Biosafety Committee (Philadelphia, PA), University of Pittsburgh IBC (Pittsburgh, Pennsylvania), University of South Florida IRB (Tampa, FL), University of Utah Institutional Biosafety Committee (Salt Lake City, UT), University of Utah IRB (Salt Lake City, UT), UTHealth \u2013 IBC (Houston, TX), VA Baltimore Research & Education Foundation (BREF)- IBC (Baltimore, MD), VA Central Arkansas Veterans Healthcare System-IBC (Little Rock, AS), VA James J. Peters Department of VA Medical Center-IBC (Bronx, NY), VA Medical Center - Atlanta-IBC (Decatur, GA), VA Medical Center San Francisco- IBC (San Francisco, CA), VA North Florida\/South Georgia IBC (Gainesville, FL), VA North Texas Health Care System IBC (Dallas, TX), VA San Diego Healthcare System IBC (Phoenix, AZ), VA Sierra Nevada Health Care System-IBC (Reno, NV), Vanderbilt University Instituitional Review Board (Nashville, TN), Washington University IBC (St Louis, MO), WCG IBCS (Houston, TX; Orlando, FL), Western Institutional Review Board (San Diego, CA; Detroit, MI; New Orleans, LA; New York, NY), WIRB - IBCS Services (Chicago, IL; New Orleans, LA; Oakland, CA; Minneapolis, MN; Columbus, OH; Lexington, KY), WJB Dorne VA Medical Center IBC (Columbia, SC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Inclusion and Ethics"}}],"article-number":"9785"}}